In 2023, the National School on X-ray and Neutron Scattering, or NXS, marked its 25th year during its annual program, held August 6–18 at the Department of Energy’s Oak Ridge and Argonne National Laboratories.
The Spallation Neutron Source — already the world’s most powerful accelerator-based neutron source — will be on a planned hiatus through June 2024 as crews work to upgrade the facility. Much of the work — part of the facility’s Proton Power Upgrade project — will involve building a connector between the accelerator and the planned Second Target Station.
Scientist Xiaohan Yang’s research at the Department of Energy’s Oak Ridge National Laboratory focuses on transforming plants to make them better sources of renewable energy and carbon storage.
Quantum computers process information using quantum bits, or qubits, based on fragile, short-lived quantum mechanical states. To make qubits robust and tailor them for applications, researchers from the Department of Energy’s Oak Ridge National Laboratory sought to create a new material system.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
Michelle Kidder, a senior R&D staff scientist at ORNL, has received the American Chemical Society’s Energy and Fuels Division’s Mid-Career Award for sustained and distinguished contributions to the field of energy and fuel chemistry.
A new nanoscience study led by a researcher at ORNL takes a big-picture look at how scientists study materials at the smallest scales.
Technologies developed by researchers at ORNL have received six 2023 R&D 100 Awards.
A group at the Department of Energy's Oak Ridge National Laboratory made a difference for local youth through hands-on projects that connected neutron science and engineering intuitively.
After a highly lauded research campaign that successfully redesigned a hepatitis C drug into one of the leading drug treatments for COVID-19, scientists at ORNL are now turning their drug design approach toward cancer.